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Risk	 for	 human	 exposure	 to	 bovine	 spongiform	
encephalopathy	 (BSE)–inducing	 agent	 was	 estimated	 in	
a nonhuman primate model. To determine attack rates, 
incubation times, and molecular signatures, we orally 
exposed	 18	 macaques	 to	 1	 high	 dose	 of	 brain	 material	
from	cattle	with	BSE.	Several	macaques	were	euthanized	
at	 regular	 intervals	starting	at	1	year	postinoculation,	and	
others were observed until clinical signs developed. Among 
those who received >5	g	BSE-inducing	agent,	attack	rates	
were	 100%	 and	 prions	 could	 be	 detected	 in	 peripheral	
tissues	 from	 1	 year	 postinoculation	 onward.	 The	 overall	
median	incubation	time	was	4.6	years	(3.7–5.3).	However,	
for	 3	 macaques	 orally	 exposed	 on	 multiple	 occasions,	
incubation	periods	were	at	least	7–10	years.	Before	clinical	
signs	 were	 noted,	 we	 detected	 a	 non-type	 2B	 signature,	
indicating	the	existence	of	atypical	prion	protein	during	the	
incubation	 period.	 This	 finding	 could	 affect	 diagnosis	 of	
variant	Creutzfeldt-Jakob	disease	in	humans	and	might	be	
relevant for retrospective studies of positive tonsillectomy 
or appendectomy specimens because time of infection 
is unknown.
Variant Creutzfeldt-Jakob disease (vCJD) (1) is most likely caused by dietary exposure to bovine spongi-
form encephalopathy (BSE) prions (2–4). In the United 
Kingdom, risk for infection with BSE has been consider-
able, but only 172 cases of vCJD have been documented 
(5–7). However, the infective dose for oral transmission 
of the BSE agent to humans is unknown, and incubation 
times can only be estimated (5,6). In 2001, the European 
Union funded a risk assessment study in nonhuman pri-
mates to estimate the risk for humans exposed to BSE-
contaminated food or blood products (8).
A determining factor for susceptibility to BSE prions is 
a polymorphism for methionine (M) or valine (V) at codon 
129 of the human prion protein gene (PRNP). All vCJD 
cases examined were methionine homozygotes at PRNP 
codon 129 (129-MM) (9). The overall distribution of PRNP 
codon 129 genotypes in the general UK population is ≈39% 
MM, ≈50% MV, and ≈11% VV (7,10). Evidently, persons 
with a 129-VV genotype can be infected (11), and clinical 
signs develop after a longer incubation time among those 
with a 129-MV genotype than among those with a 129-MM 
genotype (12). However, retrospective analyses of biopsy 
samples suggest that prevalence of BSE infection is higher 
among persons who belong to a certain birth cohort and 
lived in the United Kingdom from 1980 through 1989 (109 
cases/million persons [13] to 237 cases/million persons 
[14]). The reason for the discrepancy between the low 
number of vCJD cases and higher prevalence of infected 
persons in the United Kingdom is not known, but the 
PRNP polymorphism might contribute to this discrepancy 
as just described. Intriguingly, among hamsters that were 
orally exposed multiple times to central nervous system 
(CNS) tissues infected with the scrapie agent, incubation 
times were significantly prolonged (13). Thus, not only 
the PRNP polymorphism and the dose but also the mode 
of transmission might contribute to the development of 
subclinical cases. However, estimating exposure risks for 
humans based solely on these results is difficult because 
of the digestive physiology, life expectancy, and other 
metabolic parameters of hamsters.
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In prion diseases such as CJD, kuru, BSE, scrapie, 
and chronic wasting disease, the cellular form of prion 
protein (PrPC) is thought to be converted into abnormal PrP 
(PrPSc) through a posttranslational event. As a result, PrPSc 
becomes partially resistant to proteases. The misfolded 
prion protein comprises an N terminal protease-sensitive 
part followed by a region with variable protease sensitivity 
and a C-terminal protease-resistant core referred to as PrPres 
or PrP27–30 (Figure 1). Limited protease exposure of 
PrPSc in vitro generates nonglycosylated core fragments of 
19–21 kDa (14,15), which are used to distinguish 2 major 
PrPSc types by electrophoresis. Type 1 core protein has an 
apparent molecular mass of 21 kDa. Its primary cleavage 
site is at residue 82. Type 2 core protein migrates to the 
19-kDa region and has a primary cleavage site at residue 97 
(16,17). Both types can coexist in a considerable number 
of sporadic CJD (18,19) and vCJD cases (14). Subtypes 
and strains can be further characterized by their so-called 
glycoform profile because the nonobligatory addition 
of 1–2 sugar chains results in 3 differently glycosylated 
isoforms in PrPC and PrPSc (non-, mono-, and diglycosylated 
molecules, referred to as a PrPres triplet). In sporadic CJD 
type 2, the monoglycosylated isotype predominates and is 
referred to as a type 2A signature; whereas, in vCJD, the 
diglycosylated isoform predominates (1) and is referred 
to as a type 2B signature (14,16,19). Additional PrPres 
fragments have been described, for example the so-called 
C-terminal fragments of 12/13 kDa (20) and 17 kD (21).
Results of the European Union–funded nonhuman 
primate risk assessment study, designed to determine the 
dose at which 50% of macaques will be infected (8), show 
that a 5-g dose given on 1 occasion infected all macaques. 
Moreover, multiple exposures to high doses might prolong 
incubation time. Intriguingly, a non–type 2B PrPres pattern 
in CNS tissues of macaques during the preclinical phase 
indicated the existence of an intermediate prion isoform. 
This finding might be relevant for retrospective studies 
of tonsillectomy or appendectomy specimens, because 
the time point of infection in humans with PrPres-positive 
biopsy specimens is not known. As part of the European 
Union–funded study, we aimed to determine attack rates 
and incubation times after oral exposure to 5 g or 16 g of 
BSE-infected brain material in adult cynomolgus monkeys 
(Macaca fascicularis).
Methods
We orally exposed 18 macaques, each 5 years of age, 
to brain material from cattle with BSE: 15 macaques on 
1 occasion and 3 macaques on multiple occasions. Most 
animals were kept at the primate center of the Paul-Ehrlich-
Institut under biosafety level 3 conditions; the others 
(macaques M3–M8) were kept at the Swedish Institute 
for Infectious Disease Control, Stockholm. The study was 
approved by the Hessian Animal Protection Committee 
(local permit no. F107/45 and F107/63) and supervised by 
local authorities (Regierungspräsidium Darmstadt).
The BSE inoculum was a pool of homogenized 
bovine brain from 11 cows with natural BSE infection 
(22). The level of infectivity was determined (data not 
shown) in BoTg110 mice (23). Cynomolgus monkeys were 
purchased from the Centre de Recherche en Primatologie, 
Mauritius. All animals were homozygous for M at codon 
129 of the PRNP gene (4,22). We fed (in muesli balls, 
monitored by video to ensure that the total amount was 
eaten) 5 g of BSE inoculum to each of 12 macaques 
(macaques S1–S5 and S9–S15), 8–16 g of BSE inoculum 
to each of 6 macaques (macaques S6–S8 and C1–C3), and 
mock inoculum (non-BSE–infected brain material) to each 
of 8 macaques (macaques M1–M8). We had originally 
planned to inoculate all macaques on 1 occasion; however, 
because of feeding problems, 3 macaques (C1–C3) had to 
be inoculated on several occasions. Of these 3 macaques, 1 
received a cumulative dose of 8 g, the second 10 g, and the 
third 16 g (Table 1).
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Figure	1.	Schematic	diagram	of	the	mature	
nonglycosylated prion protein and below 
amino acid sequences of the human 
and the simian prion polypeptide chain. 
Homology	 (198/207	 aa)	 between	 human	
and simian mature cellular form of prion 
protein	 on	 the	 amino	 acid	 level	 is	 96%.	
Large and small arrows indicate major 
and minor, respectively, proteinase K 
digestion sites (14). Open arrows indicate 
digestion	 sites	 in	 type	 1	 fragments;	 filled	
arrows	 indicate	 digestion	 sites	 in	 type	 2	
fragments.	 The	 epitopes	 recognized	 by	
the used monoclonal antibodies are shown 
below. OR, octarepeat region; H, α-helical 




All animals were observed daily for any abnormalities. 
Cerebrospinal fluid (CSF) samples were collected at regular 
intervals and examined for biomarkers of brain damage by 
14–3-3 protein (14–3-3p) tests (22). We planned 2 studies. 
For study 1, BSE-infected macaques (groups I and III) were 
to be kept until development of clinical signs to determine 
incubation periods. For study 2, macaques (group II) 
received 5 g BSE brain material on 1 occasion and were 
euthanized at regular intervals during the incubation 
period (macaques S9–S15, Table 2). However, study 1 
was possible only for macaques S1–S8 (group I, Table 
2) because among macaques C1–C3 (group III, Table 2), 
non–BSE-associated disease necessitated euthanasia. 
Macaques M1–M8 were the control macaques (group IV) 
inoculated with non-BSE brain material (Table 2).
During postmortem examinations, brain, spinal cord, 
gut-associated lymphoid tissues (GALT), lymph nodes, 
tonsils, and other organs and tissues were either fixed in 
buffered formaldehyde solution (4% wt/vol) or stored 
at -80°C as described (22). Routine histopathologic 
examinations of the brains were performed to detect 
spongiform lesions in hematoxylin and eosin–stained 
tissue sections. To detect proteinase K (PK)–resistant 
PrP fragments in tissue sections, we conducted paraffin-
embedded tissue blot analyses (24). Western immunoblot 
analyses to localize PrPres in homogenized and PK–treated 
(20 µg PK/mL buffer) tissue samples (50 μg of tissue 
proteins were loaded onto a lane) were conducted as 
described (22). Western blot–negative results were retested 
by using Amersham Hyperfilm ECL (GE Healthcare, Life 
Sciences Europe, Freiburg, Germany) for visualization. 
Monoclonal antibodies and polyclonal antiserum were used 
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Table	1.	Schedule	for	successive	oral	inoculation	of	3	macaques	
with brain tissue from BSE-infected cattle* 
Macaque 
Dose, g 
Day	1 Day	2 Day	3 Day	7 Cumulative 
C1 5.0 2.0 None 1.0 8.0 
C2 6.4 2.6 None 1.0 10.0 















(spinal cord C1–T12) 
PrPres pattern 
(spinal cord L1–L4) 
Group I (clinically infected)†       
S1 F 5 4.3 Yes 2B 2B 2B 
S2 F 5 4.6 Yes 2B 2B 2B 
S3 M 5 4.7 Yes 2B 2B 2B 
S4 F 5 4.8 Yes 2B 2B 2B 
S5 F 5 5.2 Yes 2B 2B 2B 
S6‡ F 16 3.7 Yes 2B 2B 2B 
S7 F 16 4.5 Yes 2B 2B 2B 
S8 F 16 5.3 Yes 2B 2B 2B 
Group	II	(preclinical)§        
S9 M 5 1.0 No Neg Neg Neg 
S10 M 5 1.0 No Neg Neg Neg 
S11 M 5 3.0 No Neg Neg Non-2B 
S12 M 5 3.0 No Neg Neg Non-2B 
S13 M 5 3,9 No Neg Th7–10+ Neg 
S14 F 5 4,1 No Neg Neg Non-2B 
S15 F 5 5.0 No Neg Neg Non-2B 
Group	III	(preclinical)¶       
C1 F 8	 6.5 No Neg Neg Non-2B 
C2 F 10	 6.5 No Neg Neg Non-2B 
C3 F 16 8.8 No Neg Neg Neg 
Group	IV	(controls)#        
M1 F 5 2.0 No Neg Neg Neg 
M2 F 5 5.0 No Neg Neg Neg 
M3 F 16 6.0 No Neg Neg Neg 
M4 F 16 6.0 No Neg Neg Neg 
M5 F 16 6.0 No Neg Neg Neg 
M6 F 16 6.0 No Neg Neg Neg 
M7 F 0.05 6.0 No Neg Neg Neg 
M8 F 0.05 6.0 No Neg Neg Neg 
*BSE,	bovine	spongiform	encephalopathy;	PrPres, proteinase-resistant prion protein; CSF, cerebrospinal fluid; C, cervical; T, thoracic; L, lumbar; neg, 
negative. 
†Received 1 BSE dose, observed until onset of clinical signs. 
‡Macaque S6 had a highly stimulated immune system on the day of oral exposure and thereafter (reason unknown) and had the highest postmortem 
levels of proteinease-resistant prion protein (PrPres)	in	spleen	and	other	lymphoreticular	tissues	of	all	examined	macaques	(data	not	shown). 






for immunodetection (Table 3) and epitope mapping of 
PrPC and PrPSc (Figure 1). Bioassay studies were conducted 
in BoTg110 mice expressing the bovine PRNP gene (23).
Results
Among single-dosed macaques, gait ataxia developed 
in S1–S8, and CSF samples were positive for 14–3-3p from 
3.7 through 5.3 years postinoculation; no differences in 
incubation periods were noted for macaques that received 5 
g or 16 g of BSE inoculum (Table 2, Figure 2). Postmortem 
examinations of all macaques showing neurologic signs 
detected a type 2B PrPres signature in different brain areas 
(obex region, cerebellum/deep nuclei, pons, thalamus, 
caudate nucleus, cortex cerebri) and in all spinal cord 
segments examined (C1–L4) (Table 2, Figures 3, 4). The 
type 1–specific monoclonal antibody 12B2 could not detect 
any PrPres triplets in these specimens (Figure 5, panel A). 
Typical spongiform changes were seen in hemotoxylin and 
eosin–stained brain tissue sections (data not shown).
Among macaques that received 8–16 g of BSE 
inoculum (C1–C3), no behavioral changes, gait ataxia, or 
14–3-3p-positive CSF were detected. However, as they 
got older, obesity and chronically elevated blood glucose 
concentrations (>126 mg/dL) developed and were followed 
by a rapid decrease in body weight. For humane reasons, 
these animals were euthanized at 6.5 years (C1, C2) and 
8.8 years (C3) postinoculation. Retrospective analyses of 
plasma samples detected normal insulin levels at 3–4 years 
of age, followed by hyperinsulinemia and a progressive 
decline in plasma insulin levels. Postmortem examinations 
of pancreatic tissue sections indicated replacement of the 
normal islet architecture by islet-associated amyloid and 
marked reduction of α- and β-cell mass (data not shown). 
On the basis of the typical changes during the prediabetic 
phase, clinical parameters, and pancreas histopathology, 
type 2 diabetes (a common disease for nonhuman 
primates in captivity) was diagnosed. We detected neither 
spongiform changes nor PrPres deposits in the brains of 
these 3 macaques (Table 2). However, an atypical PrPres 
pattern, a 26-kDa fragment, and a 17-kDa fragment were 
found in lumbar, but not other, spinal cord segments in 2 
of the 3 macaques (Table 2, Figure 4). Paraffin-embedded 
tissue blot analyses confirmed Western immunoblot results 
(Figure 6). Paraffin-embedded tissue blot analyses of 
lymphoid tissues (GALT, lymph nodes) revealed PrPres 
deposits in 3 macaques (Table 2).
From 3 years postinoculation onward, we also detected 
an atypical PrPres pattern in lumbar spinal cord segments 
in 4 of 6 macaques that had received a single 5-g dose of 
BSE inoculum (macaques S11, S12, S14, S15; Table 2, 
Figure 4). The lumbar part of the spinal cord is probably 
the primary site of prion entry into the simian CNS after 
oral uptake of the BSE agent (data not shown). We did not 
detect histopathologic changes in hemotoxylin and eosin–
stained brain tissue sections from macaques before clinical 
signs developed (S9–S15, C1–C3).
The atypical molecular signature found in lumbar 
segments of macaques with subclinical infection was 
characterized by the predominance of a PrPres fragment, 
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Table	3.	Products	used	for	Western	immunoblot	and	paraffin-embedded	tissue	blot	analyses* 
mAb or antiserum 
Linear epitope (amino acid) 
on human PrP Source (reference) 
mAb	8B4 37–44 Santa	Cruz	Biotechnology,	Santa	Cruz,	CA,	USA 
mAb	5G5 73–85  (25) 
mAb 12B2 89	93 CIDC,	Lelystad,	the	Netherlands	(14) 
mAb	1E4 97–108 Sanquin	BV,	Amsterdam,	the	Netherlands	(14) 
mAb	3F4 109–112 Abcam,	Cambridge,	UK 
mAb	F89-160-1-5 142–152 Calbiochem/Merck4Biosciences,	Darmstadt,	Germany 
mAb	1C5 119–130 (26) 
mAb	6H4 144–152 Prionics	AG,	Schlieren,	Switzerland 
mAb	12F10 142–152 SPI-Bio/IBL	Int.,	Hamburg,	Germany 
C-20	antiserum 220–231 Santa	Cruz	Biotechnology,	Santa	Cruz,	CA,	USA 
mAb	BAR	236 213– 251 SPI-Bio/IBL	Int.,	Hamburg,	Germany 
*mAb,	monoclonal	antibody;	PrP, prion protein. 
 
Figure	2.Percentage	macaques	surviving	after	oral	inoculation	brain	







which migrated at the 17-kDa region of the sodium dodecyl 
sulfate polyacrylamide gel. A second PrPres molecule 
migrated at the area of 26 kDa but was sometimes hardly 
visible (Figure 4). Epitope mapping was conducted to 
characterize these 2 PrP molecules. Paradoxically, all 
antibodies, including monoclonal antibody 12B2 (Figure 
5, panel B), and polyclonal antiserum recognizing the 
C-terminus (data not shown) could bind to both fragments. 
Non-PrP antibodies did not bind to the atypical fragments 
(data not shown). Deglycosylation of PK–treated lumbar 
spinal cord samples by using peptide N-glycosidase F 
treatment resulted in a single band with a molecular weight 
of ≈22–23 kDa in animals with preclinical/subclinical 
infection compared with a single 19–20 kDa band in 
macaques showing neurologic signs (data not shown).
The reason for the abnormal migration behavior of the 
atypical fragments remains to be determined. When lumbar 
spinal cord tissue homogenates were intracerebrally 
inoculated into mice transgenic for the bovine PRNP 
gene, samples from symptomatic (type 2B signature) 
and asymptomatic macaques (abnormal signature) were 
infectious and caused disease in mice (53% diseased mice 
in both groups) with no statistically significant difference 
in the incubation periods (355 ± 41 vs. 372 ± 7 days 
postinoculation, respectively, Plogrank test not significant) 
(Figure 7). The percentage of mice inoculated with type 
2B or non–type 2B material that showed clinical signs was 
low, probably because of the small amount of gray matter 
(PrPres) in the inoculum; attack rates were 100% among 
mice inoculated with gray matter from brain samples (data 
not shown). Among mice infected with tissue samples 
from the asymptomatic animals, a molecular signature that 
differed from that of the inoculum developed, whereas the 
type 2B signature found in macaques showing neurologic 
signs was stable after transmission to mice (Figure 7).
Discussion
Because only a few macaques have died, it will take 
longer than previously estimated before all data from low-
dose (0.05 and 0.005 g) exposures will be available (data 
not shown). Although all macaques were originally to be 
inoculated with BSE-infected cattle brain material on only 
1 occasion, 3 of 6 macaques receiving >5 g of inoculum 
had to be fed on multiple occasions. 
The attack rate after dietary exposure to >5 g BSE brain 
material in 5-year-old adult 129-MM cynomolgus monkeys 
was 100% (18/18). PrPres deposits could be detected outside 
the GALT in gut-draining lymph nodes from at least 1 year 
postinoculation onward. These data show that the dose at 
which 50% of these nonhuman primates will be infected 
will be distinctly lower than previously estimated (4).
For single-dosed animals, the incubation period 
was 4.6 years (median, range 3.7–5.3 years). There was 
no difference between those that received 5 g and 16 g, 
indicating that <5 g represented the dose at which disease 
developed in 100% of macaques (LD100). The shortest 
incubation period was detected in macaque S6, which 
was given 16 g of inoculum on 1 occasion. This short 
incubation period might have resulted from the extremely 
high dose. However, retrospective analyses revealed that 
macaque S6 had a highly stimulated immune system (data 
not shown), which might also explain the short incubation 
period. The low variability of incubation periods (4.3–5.3 
years, excluding 3.7 years for macaque S6) was probably 
the result of the high dose. When we inoculated macaques 
with lower doses (data not shown) or when macaques were 
inoculated on multiple occasions, incubation periods were 
highly variable. After the macaques received multiple 
oral doses, clinical signs of a spongiform disease had not 
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Figure	 3.	 Western	 immunoblot	 analysis	 of	 proteinease-resistant	
prion	protein	(PrPres)	(from	brain).	The	size	of	the	nonglycosylated	
band	was	either	21	kDa	(termed	type	1,	sCJD	case	BN141)	or	19	
kDa	 (termed	 type	 2,	 sCJD	 case	 BN144).	 Diglycosylated	 PrPres	
predominated in the BSE inoculum and in all macaques showing 
neurologic	 signs	 (macaque	 S4	 is	 shown	 as	 a	 representative	
example	for	all	symptomatic	cases),	and	the	pattern	is	termed	type	
2B	to	distinguish	it	from	type	2	cases	in	which	the	monoglycosylated	
form	 predominated	 (Type	 2A,	 sCJD	 case	 BN144).	 Two	 different	
mAbs	 were	 used	 for	 routine	 immunodetection:	 6H4	 (left	 panel)	
and	 3F4	 (right	 panel).	 Blots	 were	 co-stained	 with	 a	 polyclonal	




proteinease-resistant prion protein (PrPres) (lumbar spinal cord 
segments) in preclinical and clinically ill macaques. An atypical PrPres 
pattern	was	detectable	 in	macaques	euthanized	during	 incubation	
from	3	 years	 p.i.	 (macaque	S11)	 to	 6.5	 years	 p.i.	 (macaque	C1).	
All samples were co-stained with an anti-actin-antiserum. p.i., 
postinoculation; PK, proteinase K; mAb, monoclonal antibody. 
Foodborne	Transmission	of	BSE	to	Nonhuman	Primates
developed by 6.5 (2 of 3 macaques) to 8.8 years (1 of 3 
macaques) postinoculation although they received an LD100 
on day 1 (Table 1).
Unfortunately, type 2 diabetes developed in all 3 of 
these macaques as they aged, and they had to be euthanized 
for humane reasons at the indicated time points. At 
postmortem examinations, lumbar spinal cord segments 
were PrPres positive for the 2 macaques (C1 and C2) 
euthanized 6.5 years postinoculation. We estimate that 
incubation periods in these 2 animals must be at least 7 
years because it took >6 months until PrPres deposits were 
also detectable in the cerebellum/cortex cerebri, thereby 
causing clinical signs (data not shown). In the third 
macaque (C3) euthanized 8.8 years postinoculation with 
a cumulative dose of 16 g, PrPres deposits could only be 
detected outside the CNS, thereby indicating an estimated 
incubation period >10 years. Similar results have been 
described for hamsters orally infected with the scrapie 
strain 263K on a single or multiple occasions. In that study, 
a cumulative dose significantly prolonged incubation 
periods, although hamsters were given much lower doses 
than were the macaques (13). The upper reference margin 
using 3× the standard deviation (3σ) of animal group I is 
1.52 years, corresponding to a calculated upper limit of 
the incubation period of 6.1 years after a single high-dose 
exposure (5–16 g each). This calculated incubation period 
is distinctly lower than the estimated incubation time 
of >7–10 years within animals of group III, indicating a 
biological effect of the successive BSE challenge mode on 
the incubation time in the macaque model.
The discrepancy between the low number of vCJD cases 












tissue blot analyses of lumbar 
spinal cord segments from the 
preclinical	 macaque	 S14	 (A)	
and a clinically ill macaque (B) 
for	 detection	 and	 localization	
of proteinease-resistant prion 
protein (PrPres) deposits. These 
deposits could be detected in the 
substantia gelatinosa (arrows) of 
preclinical cases. 
RESEARCH
of infected humans estimated on the basis of retrospective 
biopsy analyses (27,28) indicates the existence of pre- or 
subclinical cases, perhaps as a result of a low-dose exposure 
to BSE-contaminated material or a less susceptible PRNP 
genotype. We showed that multiple exposures to high 
doses of BSE prolonged incubation periods in a nonhuman 
primate model. These findings show that a successive BSE 
challenge mode might contribute to the development of pre- 
or subclinical cases despite a susceptible PRNP phenotype 
and an LD100. This finding is relevant because it is quite 
likely that most of the UK population has been exposed to 
BSE-contaminated food on multiple occasions (5,6).
The underlying mechanism of a prolonged incubation 
period after multiple exposures to an agent that induces 
a transmissible spongiform encephalopathy is not known 
(6,13). Theoretically, interference between types or strains 
could have caused this phenomenon, as has been shown 
by others (14,19,29,30). However, Diringer et al. (13) used 
1 well-defined laboratory scrapie strain (263K) that could 
also cause prolonged incubation periods in Syrian hamsters 
after multiple oral exposures. Their finding shows that at 
least 1 other not-yet identified mechanism causes prolonged 
incubation periods after multiple oral exposures to agents 
that induce transmissible spongiform encephalopathy.
Unexpectedly, we detected a non–type 2B PrPres 
pattern in preclinical cases from 3 years postinoculation 
onward. Transmission studies in BoTg110 mice showed 
that tissues were infectious but that this atypical molecular 
signature was not stable after the first passage to transgenic 
mice carrying the bovine PrP gene (Figure 7). However, 
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bovine spongiform encephalopathy; p.i., postinoculation; dpi, days postinoculation; PK, proteinase K; hu recPrP, human recombinant PrP.
Foodborne	Transmission	of	BSE	to	Nonhuman	Primates
the PK-sensitive N terminal part, the variable region of PK, 
and the C-terminal end were detectable in both atypical PrP 
molecules by epitope mapping studies. Thus, at least the 
17-kDa molecule showed migration behavior on sodium 
dodecyl sulfate polyacrylamide gel electrophoresis, 
which did not correlate with its formal molecular weight. 
Posttranslational modifications can cause a gel-shifting 
phenomenon (i.e., anomalous gel mobility), as observed for 
the phosphorylated tau protein (31). However, it remains to 
be determined which mechanism caused this anomalous gel 
mobility. This atypical signature probably reflects neither 
types nor strains but rather an intermediate conformation 
of the pathologic PrP.
In conclusion, the LD100 of brain from BSE-infected 
cattle for 129-MM 5-year-old adult macaques exposed 
on 1 occasion is <5 g. However, this dose did not cause 
disease within a prolonged incubation time when animals 
were exposed on multiple occasions. This finding may be 
relevant for modeling exposure risks for foodborne prion 
diseases including chronic wasting disease (32). Moreover, 
the time-dependent shift of the molecular signature might 
be relevant for retrospective analyses of biopsy samples 
most likely from animals with pre- or subclinical vCJD.
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